The combination of β-elemene and erlotinib enhanced the toxicity of primary EGFR-TKI-resistant NSCLC cells with EGFR mutation via H19-induced ferroptosis [67]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.